EntreMed, Inc., a clinical-stage biopharmaceutical company, engages in the development of oncology and antiinflammatory drugs. The company’s clinical drug candidates include Panzem (2-methoxyestradiol), which is in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis; MKC-1, a cell cycle inhibitor, which is in Phase 2 clinical trials for cancer; and ENMD-1198, a tubulin binding agent that is in Phase 1 clinical trials. Its preclinical product pipeline include 2ME2 for rheumatoid arthritis; MKC-1693, an aurora kinase inhibitor; Tubulin inhibitors that comprise a family of compounds that bind to tubulin and disrupt microtubules resulting...